JP2019532968A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532968A5
JP2019532968A5 JP2019521650A JP2019521650A JP2019532968A5 JP 2019532968 A5 JP2019532968 A5 JP 2019532968A5 JP 2019521650 A JP2019521650 A JP 2019521650A JP 2019521650 A JP2019521650 A JP 2019521650A JP 2019532968 A5 JP2019532968 A5 JP 2019532968A5
Authority
JP
Japan
Prior art keywords
sodium benzoate
polymorph
pharmaceutical composition
sodium
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019521650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532968A (ja
JP7141124B2 (ja
Filing date
Publication date
Priority claimed from US15/452,137 external-priority patent/US10336679B2/en
Application filed filed Critical
Publication of JP2019532968A publication Critical patent/JP2019532968A/ja
Publication of JP2019532968A5 publication Critical patent/JP2019532968A5/ja
Application granted granted Critical
Publication of JP7141124B2 publication Critical patent/JP7141124B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019521650A 2016-10-24 2017-10-24 安息香酸ナトリウムの多形体およびその利用 Active JP7141124B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662412160P 2016-10-24 2016-10-24
US62/412,160 2016-10-24
US15/452,137 US10336679B2 (en) 2016-10-24 2017-03-07 Polymorphic forms of sodium benzoate and uses thereof
US15/452,137 2017-03-07
PCT/CN2017/107436 WO2018077157A1 (en) 2016-10-24 2017-10-24 Polymorphic forms of sodium benzoate and uses thereof

Publications (3)

Publication Number Publication Date
JP2019532968A JP2019532968A (ja) 2019-11-14
JP2019532968A5 true JP2019532968A5 (cg-RX-API-DMAC7.html) 2020-10-01
JP7141124B2 JP7141124B2 (ja) 2022-09-22

Family

ID=61970963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019521650A Active JP7141124B2 (ja) 2016-10-24 2017-10-24 安息香酸ナトリウムの多形体およびその利用

Country Status (10)

Country Link
US (1) US10336679B2 (cg-RX-API-DMAC7.html)
EP (1) EP3529229B1 (cg-RX-API-DMAC7.html)
JP (1) JP7141124B2 (cg-RX-API-DMAC7.html)
KR (1) KR102511444B1 (cg-RX-API-DMAC7.html)
CN (1) CN110167909B (cg-RX-API-DMAC7.html)
CA (1) CA3041389A1 (cg-RX-API-DMAC7.html)
IL (2) IL266210B (cg-RX-API-DMAC7.html)
MX (1) MX2019004734A (cg-RX-API-DMAC7.html)
TW (5) TWI784662B (cg-RX-API-DMAC7.html)
WO (1) WO2018077157A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017215593A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
AU2018371628B2 (en) 2017-11-22 2021-08-12 Excelsior Pharmatech Labs Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
US20210186937A1 (en) * 2018-05-22 2021-06-24 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US20220304962A1 (en) * 2019-04-24 2022-09-29 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2021245697A1 (en) 2020-06-01 2021-12-09 Celagenex Research (India) Pvt. Ltd. Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling
US20260041657A1 (en) * 2024-08-09 2026-02-12 Hsien-Yuan Lane Benzoate for use in preventing or treating cognitive dysfunction

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498989A (en) 1969-04-16 1970-03-03 American Home Prod Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en) 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4041174A (en) 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5198217A (en) * 1991-09-24 1993-03-30 Choice Pharmaceuticals Topical demulcent for viral and inflammatory diseases of the skin
FR2700117B1 (fr) 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) 1993-11-26 1995-06-01 Karla Dr Lehmann Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6255089B1 (en) * 1997-02-27 2001-07-03 Albany Medical College Constitutively activated serotonin receptors
IN191496B (cg-RX-API-DMAC7.html) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
US6362226B2 (en) * 1999-12-08 2002-03-26 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US20030185754A1 (en) 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
CA2433866A1 (en) 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
JP2006526635A (ja) 2003-06-02 2006-11-24 サマリタン,ファーマスーティカルス,インク. 血清中コルチゾール量を調節する方法および組成物
ZA200605384B (en) 2003-12-29 2007-10-31 Sepracor Inc Benzo[D]isoxazol-3-OL DAAO inhibitors
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
BRPI0509592A (pt) 2004-05-06 2007-09-25 Cydex Inc formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006129160A2 (en) 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
US20110045065A1 (en) 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0603181D0 (en) 2006-02-17 2006-03-29 Merck Sharp & Dohme Treatment of neurodegenerative and psychiatric diseases
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
WO2008034087A2 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
US8263652B2 (en) 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
MX353752B (es) * 2009-01-20 2018-01-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco.
DE212014000063U1 (de) * 2014-03-24 2015-10-12 China Medical University Verwendung von Benzoesäuresalz bei der Herstellung einer Zusammensetzung zur Prävention oder Behandlung von Demenz oder leichter kognitiver Beeinträchtigung
US10064833B2 (en) 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
US10098861B1 (en) * 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Similar Documents

Publication Publication Date Title
CN107868071B (zh) 7,8-二羟黄酮和7,8-取代的黄酮衍生物、组合物及其相关方法
CA3236624A1 (en) Formulations of psilocybin analogs and methods of use
CN109890391B (zh) 痴呆症的治疗
CN102204904B (zh) 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用
KR20210100667A (ko) 신경 또는 정신 장애의 치료 방법
CA2492081A1 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2017147375A1 (en) Amphetamine controlled release, prodrug, and abuse deterrent dosage forms
US12161758B2 (en) Modified release formulations and uses thereof
JP2022500397A (ja) サイクロセリン化合物の塩およびそれらの用途
JP2019532968A (ja) 安息香酸ナトリウムの多形体およびその利用
JP2019501207A (ja) バレニクリンまたはこの薬学的に許容可能な塩を含有する、味の遮蔽された口腔投与用薬学製剤
JP2022535894A (ja) 放出調節製剤およびその使用
JP2016026231A (ja) 式(i)の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
JPS5938203B2 (ja) 補酵素qを主成分とする脳循環障害治療剤
JP2022050553A (ja) アルツハイマー病の治療のためのanavex2-73
JP2016520556A (ja) Nsaid投与並びに関連する組成物、方法及びシステム
US20230218623A1 (en) Salts of neuroceuticals and uses thereof
JP3560970B2 (ja) ベンゾフルメトールを含有する抗マラリア性の相乗作用組成物
JP5386476B2 (ja) 頭蓋外傷の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシド−4−ピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用
CN114080221B (zh) 用于减轻疼痛的布洛芬与曲马多的组合
CN120459077B (zh) 酪醇硫酸钠及衍生酪醇化合物在制备脑健康产品中的应用
CN102079717A (zh) 一种二元酯酸的精氨酸盐化合物及其制备方法和药物应用
AU2015282909A1 (en) Novel polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's
CN105748460A (zh) 一种治疗老年痴呆的药物
CN105769882A (zh) 一种抑制血栓形成的药物组合物及其用途